EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5300
+0.0251 (+4.97%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.5049
Open0.5300
Bid0.36 x 1000
Ask0.54 x 1800
Day's Range0.5008 - 0.5300
52 Week Range0.2750 - 1.3400
Volume254,022
Avg. Volume1,383,115
Market Cap23.025M
Beta (3Y Monthly)2.78
PE Ratio (TTM)N/A
EPS (TTM)-0.38
Earnings DateFeb 28, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Research16 days ago

    EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE?

    EyeGate (EYEG) announced Q3 financial results and provided a business update. To-date, EYEG has received $13.8M in upfront and milestones under the two agreements, including ~$300k in the most recent quarter. While the yoy decrease reflects a change in activity from the relatively large EGP-437 trials to the smaller OBG studies, the qoq increase is a result of continued progression of both OBG programs.

  • GlobeNewswire25 days ago

    Investor Expectations to Drive Momentum within Atomera, YogaWorks, Cellect Biotechnology, Eyegate Pharmaceuticals, Zealand Pharma A/S, and Polar Power — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRElast month

    Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity

    HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Shares of EyeGate exploded on Tuesday on tremendous volume after reporting third quarter financial results. Shares of Viking Therapeutics were little changed ...

  • GlobeNewswirelast month

    EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today announced financial results for the three-month period ended September 30, 2018 and provided an update on recent corporate and operational activities. Stephen From, EyeGate’s Chief Executive Officer, said, “The third quarter of 2018 was a transformative quarter for EyeGate, with the Company receiving FDA approval for two IDE submissions for our Ocular Bandage Gel ('OBG') product, as well as focusing our efforts toward the key clinical trials that support this innovative product.” Mr. From continued, “We are extremely pleased to have announced positive top-line data in each of our OBG studies for photorefractive keratectomy ('PRK') surgery and punctate epitheliopathies ('PE').

  • ACCESSWIRElast month

    4 Healthcare Stocks Investors Are Watching In November

    Eighty-three percent of healthcare organizations responding to an American Telemedicine Association* poll said they are highly likely to invest in telehealth with operational efficiency and convenience in mind. Of the 171 healthcare executives participating in the annual ATA Executive Leadership Survey, 88% of those who are likely to purchase telehealth tools are planning to do so. "This executive leadership survey confirms undeniably today's leaders view telemedicine as a major driver in transforming healthcare," said Jonathan Linkous, CEO, American Telemedicine Association.

  • GlobeNewswirelast month

    EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study

    EyeGate Pharmaceuticals, Inc. (EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage patients with punctate epitheliopathies (PE) due to pathologies such as dry eye. Randall J Olson, M.D., CEO and Chair of the Department of Ophthalmology and Visual Sciences of the John A. Moran Eye Center, University of Utah, SLC, said, “A product that achieves symptomology results as seen in this study is exactly what ophthalmologists want access to when treating patients. This controlled, masked study enrolled 30 subjects with punctate epitheliopathies (PE) due to pathologies such as dry eye.

  • GlobeNewswirelast month

    EyeGate Pharma Announces Positive Results in Second PRK Study

    EyeGate Pharmaceuticals, Inc. (EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage corneal epithelial defects in patients following photorefractive keratectomy (PRK) surgery, compared to current standard of care. Daniel S. Durrie, M.D., Founder, Durrie Vision in Overland Park, KS, said, “This is the first time I have seen a product heal an epithelial defect without a bandage contact lens. The PRK study enrolled 45 subjects undergoing a bilateral PRK procedure.

  • GlobeNewswire2 months ago

    EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care

    EyeGate Pharmaceuticals, Inc. (EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today the execution of a license agreement with SentrX™ Animal Care, Inc., a veterinary medical device company that develops and manufactures veterinary wound care products. Under the agreement, EyeGate will in-license the rights to trade-secrets and know-how related to the manufacturing of EyeGate’s Ocular Bandage Gel (OBG). The agreement will enable EyeGate to pursue a different vendor with a larger capacity for manufacturing and an FDA-inspected facility for commercialization of a product for human use.

  • Zacks Small Cap Research3 months ago

    EYEG: Focus Is On OBG As U.S. Pilot Studies Fully Enrolled. Data Expected Q4. EGP-437 Ph3 AE Data Disappoints

    EyeGate (EYEG) reported Q2 2018 financial results and provided a business update. Through Q2, EYEG collected $13.5M from Valeant related to upfront payments and development milestones associated with the development agreements for EGP-437 in anterior uveitis and post-cataract surgery. In terms of how these payments are recognized on EYEG’s financial statements, as a reminder an updated FASB standard governing revenue-recognition for contracts with customers resulted in a $9.5M adjustment to EYEG’s deferred revenue balance (as of Jan 1, 2018) – this is solely an accounting adjustment with no cash effect.

  • GlobeNewswire3 months ago

    EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules

    EyeGate Pharmaceuticals, Inc. (EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the Company has been granted an additional 180 days to comply with Nasdaq’s continued listing rules. EyeGate is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products developing and commercializing products using its two proprietary platform technologies for treating diseases and disorders of the eye. EyeGate’s CMHA-S platform, EyeGate OBG, is based on a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface.

  • GlobeNewswire3 months ago

    EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies

    EyeGate Pharmaceuticals, Inc. (EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today that patient enrollment is complete in the next two pilot studies using the Hyaluronic Acid (HA) polymer for both photorefractive keratectomy (PRK) and punctate epitheliopathies (PE). The Company is also on track to report top-line data from both studies in the fourth quarter of 2018, which evaluate the efficacy of EyeGate’s Ocular Bandage Gel (OBG) HA in wound healing.

  • Zacks Small Cap Research5 months ago

    EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Off

    As we noted in our Q1 ’18 earnings update in late-May, Eyegate Pharmaceuticals' (EYEG) diligence in rapidly responding to FDAs follow-on questions related to their IDE submission has been key to keeping their Ocular Bandage Gel (OBG) programs on-track with updated forecasted timelines. EYEG had previously been guiding for commencement of both studies during Q3 (i.e.

  • EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24
    Market Realist5 months ago

    EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24

    On July 24, EyeGate Pharmaceuticals (EYEG) announced that it has secured FDA approval for two investigational device exemption applications related to pilot studies for the company’s OBG (ocular bandage gel) product scheduled to commence in the third quarter. In one pivotal study, the company will compare the OBG (or CHMA-S) product with the combination of bandage contact lens and artificial tears, which is the current standard of care for patients who have undergone photorefractive keratectom and require accelerated re-epithelialization of the corneal wounds.

  • ACCESSWIRE5 months ago

    Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on FGEN sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com evaluates EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT), Fate Therapeutics Inc. (NASDAQ: FATE), and FibroGen Inc. (NASDAQ: FGEN).

  • ACCESSWIRE6 months ago

    Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia

    LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want access to our free research report on FibroGen, Inc. (NASDAQ: FGEN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=FGEN as the Company's latest news hit the wire. On June 07, 2018, the Company announced that it has completed patient enrollment in the Phase-3 studies supporting the US new drug application (NDA) submission for Roxadustat in anemia associated with chronic kidney disease (CKD).